OnCo

Stay in the loop

Leave your email and OnCo will write when something big changes in cancer research. No spam, one click to unsubscribe.

Email updates open shortly. Until then, press Watch on any page to keep it on your list.

trialsTrialActive

Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer

A phase 1/2 trial of Oregovomab, Bevacizumab, Paclitaxel / nab-paclitaxel in ovarian cancer, run by CanariaBio Inc., active and no longer recruiting.